Immunization with V987H-stabilized Spike glycoprotein protects K18-hACE2 mice and golden Syrian hamsters upon SARS-CoV-2 infection.

Publication date: Mar 21, 2024

Safe and effective severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are crucial to fight against the coronavirus disease 2019 pandemic. Most vaccines are based on a mutated version of the Spike glycoprotein [K986P/V987P (S-2P)] with improved stability, yield and immunogenicity. However, S-2P is still produced at low levels. Here, we describe the V987H mutation that increases by two-fold the production of the recombinant Spike and the exposure of the receptor binding domain (RBD). S-V987H immunogenicity is similar to S-2P in mice and golden Syrian hamsters (GSH), and superior to a monomeric RBD. S-V987H immunization confer full protection against severe disease in K18-hACE2 mice and GSH upon SARS-CoV-2 challenge (D614G or B. 1.351 variants). Furthermore, S-V987H immunized K18-hACE2 mice show a faster tissue viral clearance than RBD- or S-2P-vaccinated animals challenged with D614G, B. 1.351 or Omicron BQ1. 1 variants. Thus, S-V987H protein might be considered for future SARS-CoV-2 vaccines development.

Open Access PDF

Concepts Keywords
D614g 2p
Low Cov
Pandemic Glycoprotein
Syrian Golden
Vaccines Hace2


Type Source Name
disease VO immunization
disease VO Glycoprotein
disease MESH SARS-CoV-2 infection
pathway REACTOME SARS-CoV-2 Infection
disease VO effective
disease VO Severe acute respiratory syndrome coronavirus 2
disease IDO production
drug DRUGBANK Glutathione
disease VO immunized
disease VO vaccinated
disease VO vaccine
disease MESH emergency
disease VO time
disease MESH Middle East respiratory syndrome
drug DRUGBANK Angiotensin II
disease IDO host
disease MESH infection
disease VO Respiratory syncytial virus
disease VO vaccination
drug DRUGBANK Aluminium phosphate
disease VO unvaccinated
pathway KEGG Viral replication
disease MESH weight reduction

Original Article

(Visited 1 times, 1 visits today)